Avenue Therapeutics, Inc. (NASDAQ:ATXI – Get Free Report)’s share price was down 21.7% during mid-day trading on Monday . The company traded as low as $0.4520 and last traded at $0.4520. Approximately 308 shares traded hands during mid-day trading, a decline of 95% from the average session volume of 6,020 shares. The stock had previously closed at $0.5770.
Avenue Therapeutics Stock Performance
The stock’s 50-day moving average is $0.31 and its two-hundred day moving average is $0.33. The stock has a market cap of $1.71 million, a PE ratio of 0.03 and a beta of -0.20.
About Avenue Therapeutics
Avenue Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for disorders of the central nervous system, with an initial emphasis on acute pain management. The company’s research and development efforts are centered on reformulating established active pharmaceutical ingredients to address unmet needs in hospital and outpatient settings, aiming to improve safety profiles, reduce opioid exposure and support enhanced patient recovery.
The company’s lead product candidate is intravenous tramadol, a unique non-solicited opioid analgesic that combines dual mechanisms of action to manage moderate to severe acute pain.
Read More
- Five stocks we like better than Avenue Therapeutics
- What Does Apple’s TV Price Hike Say About Where the Stock Is Heading?
- Will the Most Successful Quantum Firms Be Software Companies?
- Dutch Bros Sell-Off Creates a Growth Opportunity
- NVIDIA’s MediaTek Bet Shows How It Plans to Defend Its AI Moat
Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
